Symphony Financial’s Biogen BIIB Stock Holding History

Symphony Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,018	Closed	-$322K	–	136
2020 Q1	$322K	Buy	+1,018	New	+$309K	0.22%	69

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Symphony Financial's BIIB Position: Q2 2020 in Review

Symphony Financial sold out of Biogen (BIIB) in Q2 2020, closing a stake of 1,018 shares — an estimated $322K sold.

Symphony Financial first reported a position in BIIB in Q1 2020 and held it in 1 quarter. The position peaked at $322K in Q1 2020. 1,059 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

Symphony Financial reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
Symphony Financial sold 1,018 Biogen shares in Q2 2020, an estimated $322K.
Symphony Financial first reported a position in Biogen in Q1 2020 and held it in 1 quarter.
Symphony Financial's Biogen position peaked at $322K in Q1 2020.
1,059 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Symphony Financial's 13F filing for Q2 2020, filed 8 Jul 2020.